Literature DB >> 34850120

Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity.

Ken Yamada1, Samuel Hildebrand1, Sarah M Davis1, Rachael Miller1,2, Faith Conroy1,2, Ellen Sapp3, Jillian Caiazzi1, Julia F Alterman1, Loic Roux1, Dimas Echeverria1, Matthew R Hassler1, Edith L Pfister2, Marian DiFiglia3, Neil Aronin1,2, Anastasia Khvorova1,4.   

Abstract

Oligonucleotides is an emerging class of chemically-distinct therapeutic modalities, where extensive chemical modifications are fundamental for their clinical applications. Inter-nucleotide backbones are critical to the behaviour of therapeutic oligonucleotides, but clinically explored backbone analogues are, effectively, limited to phosphorothioates. Here, we describe the synthesis and bio-functional characterization of an internucleotide (E)-vinylphosphonate (iE-VP) backbone, where bridging oxygen is substituted with carbon in a locked stereo-conformation. After optimizing synthetic pathways for iE-VP-linked dimer phosphoramidites in different sugar contexts, we systematically evaluated the impact of the iE-VP backbone on oligonucleotide interactions with a variety of cellular proteins. Furthermore, we systematically evaluated the impact of iE-VP on RNA-Induced Silencing Complex (RISC) activity, where backbone stereo-constraining has profound position-specific effects. Using Huntingtin (HTT) gene causative of Huntington's disease as an example, iE-VP at position 6 significantly enhanced the single mismatch discrimination ability of the RISC without negative impact on silencing of targeting wild type htt gene. These findings suggest that the iE-VP backbone can be used to modulate the activity and specificity of RISC. Our study provides (i) a new chemical tool to alter oligonucleotide-enzyme interactions and metabolic stability, (ii) insight into RISC dynamics and (iii) a new strategy for highly selective SNP-discriminating siRNAs.
© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34850120      PMCID: PMC8643693          DOI: 10.1093/nar/gkab1126

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  63 in total

1.  Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain.

Authors:  Jin-Biao Ma; Keqiong Ye; Dinshaw J Patel
Journal:  Nature       Date:  2004-05-20       Impact factor: 49.962

2.  Coupled 5' nucleotide recognition and processivity in Xrn1-mediated mRNA decay.

Authors:  Martin Jinek; Scott M Coyle; Jennifer A Doudna
Journal:  Mol Cell       Date:  2011-03-04       Impact factor: 17.970

Review 3.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

4.  Chirality Dependent Potency Enhancement and Structural Impact of Glycol Nucleic Acid Modification on siRNA.

Authors:  Mark K Schlegel; Donald J Foster; Alexander V Kel'in; Ivan Zlatev; Anna Bisbe; Muthusamy Jayaraman; Jeremy G Lackey; Kallanthottathil G Rajeev; Klaus Charissé; Joel Harp; Pradeep S Pallan; Martin A Maier; Martin Egli; Muthiah Manoharan
Journal:  J Am Chem Soc       Date:  2017-06-19       Impact factor: 15.419

5.  Re-Engineering RNA Molecules into Therapeutic Agents.

Authors:  Martin Egli; Muthiah Manoharan
Journal:  Acc Chem Res       Date:  2019-03-26       Impact factor: 22.384

6.  Structural Analysis of Human Argonaute-2 Bound to a Modified siRNA Guide.

Authors:  Nicole T Schirle; Garth A Kinberger; Heather F Murray; Walt F Lima; Thazha P Prakash; Ian J MacRae
Journal:  J Am Chem Soc       Date:  2016-07-12       Impact factor: 15.419

7.  5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo.

Authors:  Reka A Haraszti; Loic Roux; Andrew H Coles; Anton A Turanov; Julia F Alterman; Dimas Echeverria; Bruno M D C Godinho; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2017-07-27       Impact factor: 16.971

8.  Targeting Huntingtin Expression in Patients with Huntington's Disease.

Authors:  Sarah J Tabrizi; Blair R Leavitt; G Bernhard Landwehrmeyer; Edward J Wild; Carsten Saft; Roger A Barker; Nick F Blair; David Craufurd; Josef Priller; Hugh Rickards; Anne Rosser; Holly B Kordasiewicz; Christian Czech; Eric E Swayze; Daniel A Norris; Tiffany Baumann; Irene Gerlach; Scott A Schobel; Erika Paz; Anne V Smith; C Frank Bennett; Roger M Lane
Journal:  N Engl J Med       Date:  2019-05-06       Impact factor: 91.245

9.  Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain.

Authors:  Julia F Alterman; Lauren M Hall; Andrew H Coles; Matthew R Hassler; Marie-Cecile Didiot; Kathryn Chase; Jasmin Abraham; Emily Sottosanti; Emily Johnson; Ellen Sapp; Maire F Osborn; Marian Difiglia; Neil Aronin; Anastasia Khvorova
Journal:  Mol Ther Nucleic Acids       Date:  2015-12-01       Impact factor: 10.183

Review 10.  Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.

Authors:  Xiulong Shen; David R Corey
Journal:  Nucleic Acids Res       Date:  2018-02-28       Impact factor: 16.971

View more
  1 in total

1.  Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.

Authors:  Faith Conroy; Rachael Miller; Julia F Alterman; Matthew R Hassler; Dimas Echeverria; Bruno M D C Godinho; Emily G Knox; Ellen Sapp; Jaquelyn Sousa; Ken Yamada; Farah Mahmood; Adel Boudi; Kimberly Kegel-Gleason; Marian DiFiglia; Neil Aronin; Anastasia Khvorova; Edith L Pfister
Journal:  Nat Commun       Date:  2022-10-03       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.